JP2018513852A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513852A5
JP2018513852A5 JP2017552451A JP2017552451A JP2018513852A5 JP 2018513852 A5 JP2018513852 A5 JP 2018513852A5 JP 2017552451 A JP2017552451 A JP 2017552451A JP 2017552451 A JP2017552451 A JP 2017552451A JP 2018513852 A5 JP2018513852 A5 JP 2018513852A5
Authority
JP
Japan
Prior art keywords
sodium
pharmaceutical composition
ibrutinib
composition according
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017552451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026134 external-priority patent/WO2016164404A1/en
Publication of JP2018513852A publication Critical patent/JP2018513852A/ja
Publication of JP2018513852A5 publication Critical patent/JP2018513852A5/ja
Priority to JP2021181761A priority Critical patent/JP7438178B2/ja
Priority to JP2023193108A priority patent/JP2024026087A/ja
Priority to JP2026050359A priority patent/JP2026116969A/ja
Withdrawn legal-status Critical Current

Links

JP2017552451A 2015-04-06 2016-04-06 イブルチニブを含有する組成物 Withdrawn JP2018513852A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021181761A JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物
JP2026050359A JP2026116969A (ja) 2015-04-06 2026-03-25 イブルチニブを含有する組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
US62/143,659 2015-04-06
PCT/US2016/026134 WO2016164404A1 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021181761A Division JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物

Publications (2)

Publication Number Publication Date
JP2018513852A JP2018513852A (ja) 2018-05-31
JP2018513852A5 true JP2018513852A5 (enExample) 2019-05-16

Family

ID=55806788

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017552451A Withdrawn JP2018513852A (ja) 2015-04-06 2016-04-06 イブルチニブを含有する組成物
JP2021181761A Active JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A Pending JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物
JP2026050359A Pending JP2026116969A (ja) 2015-04-06 2026-03-25 イブルチニブを含有する組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021181761A Active JP7438178B2 (ja) 2015-04-06 2021-11-08 イブルチニブを含有する組成物
JP2023193108A Pending JP2024026087A (ja) 2015-04-06 2023-11-13 イブルチニブを含有する組成物
JP2026050359A Pending JP2026116969A (ja) 2015-04-06 2026-03-25 イブルチニブを含有する組成物

Country Status (29)

Country Link
US (6) US20160287594A1 (enExample)
EP (3) EP3892302B8 (enExample)
JP (4) JP2018513852A (enExample)
KR (2) KR20240013859A (enExample)
CN (2) CN107530293A (enExample)
AU (4) AU2016246669B2 (enExample)
CA (1) CA2981601A1 (enExample)
CL (1) CL2017002512A1 (enExample)
DK (1) DK3892302T3 (enExample)
EA (1) EA033992B1 (enExample)
ES (1) ES2964472T3 (enExample)
FI (1) FI3892302T3 (enExample)
HK (1) HK1250925A1 (enExample)
HR (1) HRP20231207T1 (enExample)
HU (1) HUE063751T2 (enExample)
IL (2) IL295941A (enExample)
LT (1) LT3892302T (enExample)
MA (2) MA54411B1 (enExample)
MD (1) MD3892302T2 (enExample)
MX (2) MX2017012822A (enExample)
PH (1) PH12017501811A1 (enExample)
PL (1) PL3892302T3 (enExample)
PT (1) PT3892302T (enExample)
RS (1) RS64653B1 (enExample)
SG (2) SG11201707989PA (enExample)
SI (1) SI3892302T1 (enExample)
SM (1) SMT202300422T1 (enExample)
UA (1) UA125681C2 (enExample)
WO (1) WO2016164404A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3892302B8 (en) 2015-04-06 2023-10-18 Janssen Pharmaceutica NV Compositions containing ibrutinib
CN109790121B (zh) 2016-10-06 2024-01-05 詹森药业有限公司 用于制备btk抑制剂的方法和中间体
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
US11576917B2 (en) 2018-01-20 2023-02-14 Natco Pharma Limited Pharmaceutical compositions comprising Ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
KR102844084B1 (ko) * 2018-06-15 2025-08-07 얀센 파마슈티카 엔브이 이브루티닙을 포함하는 제형/조성물
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
JP2022513666A (ja) * 2018-11-30 2022-02-09 ヤンセン バイオテツク，インコーポレーテツド 濾胞性リンパ腫の治療方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
TN2023000295A1 (en) * 2021-06-10 2025-07-02 Hikma Pharmaceuticals Usa Inc Oral dosage forms of ibrutinib
CN117064862B (zh) * 2023-04-10 2025-12-19 山东新时代药业有限公司 一种伊布替尼肠溶片及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK607188A (da) 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
DE10201304A1 (de) 2002-01-15 2003-07-31 Infineon Technologies Ag Nichtflüchtige Halbleiter -Speicherzelle sowie zugehöriges Herstellungsverfahren
WO2006116596A2 (en) * 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
WO2014142678A1 (en) 2013-03-14 2014-09-18 Fisher & Paykel Healthcare Limited Catheter mount with suction port
CN104119350B (zh) 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
CA2920821A1 (en) * 2013-08-12 2015-02-19 The Yokohama Rubber Co., Ltd. Primer composition
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
WO2015140709A1 (en) 2014-03-19 2015-09-24 Novartis Ag Solid pharmaceutical dosage forms
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
EP3892302B8 (en) 2015-04-06 2023-10-18 Janssen Pharmaceutica NV Compositions containing ibrutinib
MX2018014577A (es) 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.

Similar Documents

Publication Publication Date Title
AU2026200996A1 (en) Compositions containing Ibrutinib
HRP20201316T1 (hr) Novi modulatori receptora sfingozin-fosfata
US20110172210A1 (en) Method for titrating clozapine
NZ589445A (en) Rasagiline for parkinson's disease modification
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
HU229312B1 (hu) Szabályozott hatóanyag-leadású gyógyszer-dózisformák legalább egy idõzített gyors szakaszt magába foglaló szabályozott hatóanyag-leadásra
JP2018507243A5 (enExample)
CA2802093A1 (en) Combination therapy with lisdexamphetamine and extended release guanfacine
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
KR20100008356A (ko) 칼슘채널길항제를 포함하는 약제학적 제제
JP2015510916A5 (enExample)
JP2021152060A (ja) アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
RU2016137926A (ru) Композиции грапипранта и способы их применения
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
JP2011516544A5 (enExample)
NO20062082L (no) Pellets inneholdende venlafaksinhydroklorid
MX2008011020A (es) Compuestos de receptor sigma.
JP2016505050A5 (enExample)
HRP20151321T1 (hr) Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
CA3091329A1 (en) Extended-release pharmaceutical composition containing lacosamide
HRP20251123T1 (hr) Ekopipam za liječenje touretteovog sindroma
CN108524498A (zh) 药物组合物
KR101497354B1 (ko) 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
AU2007234917A1 (en) Renin inhibitors for the treatment of hypertension